For the three months ending December 31, ResMed
(ASX:RMD) delivered revenue of US$651.1 million, which was an increase of 8 per cent on the prior corresponding period.
The sleep treatment medical device net operating profit increased 8 per cent.
Revenue in the US, Canada, and Latin America, excluding Software as a Service, grew by 9 percent compared to the prior year period, driven by strong sales across their mask and device product portfolios.
Shares in Resmed
(ASX:RMD) are trading 8.45 per cent lower at $15.06.
